Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib combinations in HRD+ HER2- advanced breast cancer
NCT05085626Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Feb 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
fluzoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05085626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085626.